AstraZeneca and Pelago to collaborate on joint research projects

Published: 30-Nov-2015
Research & Development

AstraZeneca gains licence to use and apply Cellular Thermal Shift Assay (CETSA) method to determine drug/target interactions


Drugmaker AstraZeneca has entered into a two-year research collaboration and licensing agreement with Swedish firm Pelago Bioscience.

Under the agreement, the firms will work together on joint projects and AstraZeneca will also be granted a licence to use and apply Pelago's Cellular Thermal Shift Assay (CETSA) for determining and quantifying drug/target interactions in other AstraZeneca discovery projects.

No financial details have been revealed.

The partners will together develop assay formats and applications of the CETSA method relevant across the therapeutic areas covered by AstraZeneca. They will share information related to benchmarking and improvement in the use of the technology.

  • Companies:
  • AstraZeneca
  • Pelago Bioscience
See more

You may also like

Research & Development

AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion

Read more
The acquisition will facilitate the development of novel therapeutics for rare endocrine and related diseases

Trending Articles

  1. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  2. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D
  3. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  4. Naobios and Sumagen sign exclusive partnership to develop HIV vaccine Naobios will manage process development and initiate launch of cGMP manufacturing for phase II clinical trials
  5. Lonza aims to tackle bias concerns during blinded clinical trials Lonza has introduced an over-encapsulation product aimed at tackling concerns around bias during blinded clinical trials

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion

The acquisition will facilitate the development of novel therapeutics for rare endocrine and related diseases
Research & Development

Fasenra could initiate remission in patients with EGPA, study finds

MANDARA Phase III data highlights remission as an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with monthly subcutaneous injections of Fasenra
Manufacturing

Sodexo and AstraZeneca extend global partnership

Sodexo reinforces its contract of food and facilities management services with AstraZeneca in the UK, and Scandinavia for a further five years
Research & Development

Third cancer drug success for Astex drug discovery collaboration

AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN)
Research & Development

AstraZeneca meets primary endpoint in MANDARA Phase III trial

The pharma giant has revealed the results of the first head-to-head trial of biologics in EGPA, comparing a single monthly injection of the Fasenra drug to three injections per month of mepolizumab
Research & Development

AstraZeneca and Daiichi Sankyo reveal phase 3 lung cancer study

Results for the TROP2-directed antibody drug conjugate demonstrated statistically significant improvement in progression-free survival vs. standard chemotherapy
Drug Delivery

Quell signs licence with AstraZeneca for Treg cell therapies

Quell’s proprietary toolbox of Treg cell engineering modules will be leveraged to develop autologous multi-modular Treg cell therapy candidates for Type 1 Diabetes
Subscribe now